Factor VII and extrinsic pathway inhibitor in acute coronary disease.
This report describes studies on the activation of coagulation factor VII (FVII) and the inhibition of the extrinsic coagulation pathway in acute ischaemic heart disease. FVII and the inhibitor of the tissue thromboplastin-FVII complex, called extrinsic pathway inhibitor (EPI), were determined in plasma from 68 patients and compared to findings in 37 normal individuals. The mean FVII amidolytic activity, the mean FVII clotting activity, as well as the FVII clotting/FVII amidolytic ratio were not significantly different in the patient groups as compared to the controls. The fraction of FVII clotting activity that is sensitive to phospholipase C, 'the FVII-phospholipid complex', was 8% in controls, 19% (P less than 0.05) in patients with acute myocardial infarction, 15% (n.s.) in angina pectoris and 13% (n.s.) in heart failure/arrhythmia patients. The 'FVII-phospholipid complex' was highly significantly correlated to triglycerides in plasma in patients with acute myocardial infarction (r = 0.88, P less than 0.001) and angina pectoris (r = 0.89, P less than 0.001). The mean EPI levels were significantly increased in patients with acute myocardial infarction (132%), angina pectoris (134%), and heart failure (150%) as compared to the control population (110%). The FVII clotting/EPI ratio was significantly decreased both in patients with acute myocardial infarction and heart failure, whereas the FVII amidolytic/EPI ratio was significantly decreased only in the heart failure group. Apparently, in patients with acute ischaemic heart disease, a moderate increase in the procoagulant activity is accompanied by a marked increase in the anticoagulant activity of the extrinsic coagulation pathway, suggesting a balanced activation system.
Sandset
P M
PM
Medical Department, Aker Hospital, University of Oslo, Norway.
Sirnes
P A
PA
Abildgaard
U
U
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000097:blood; D000941:Antigens / Q000032:analysis; D003327:Coronary Disease / Q000097:blood*; D005167:Factor VII / Q000032:analysis* / Q000037:antagonists & inhibitors / Q000276:immunology; D015942:Factor VIIa; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood; D010743:Phospholipids / Q000097:blood; D013925:Thromboplastin / Q000032:analysis* / Q000037:antagonists & inhibitors; D014280:Triglycerides / Q000097:blood
D000941:Antigens; D008074:Lipoproteins; D010743:Phospholipids; D014280:Triglycerides; C042580:factor VII clotting antigen; C051928:lipoprotein-associated coagulation inhibitor; D005167:Factor VII; D013925:Thromboplastin; D015942:Factor VIIa